| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.21▲ | 3.24▼ | 3.25▼ | 4.33▼ | 4.08▼ |
| MA10 | 3.22▲ | 3.24▼ | 3.31▼ | 4.31▼ | 3.90▼ |
| MA20 | 3.22▲ | 3.35▼ | 3.95▼ | 4.14▼ | 3.40▼ |
| MA50 | 3.26▼ | 4.18▼ | 4.35▼ | 3.89▼ | 3.79▼ |
| MA100 | 3.31▼ | 4.34▼ | 4.21▼ | 3.27▼ | 5.47▼ |
| MA200 | 3.84▼ | 4.20▼ | 4.03▼ | 3.18▲ | 4.85▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.045▲ | -0.057▼ | -0.088▼ | 0.131▲ |
| RSI | 47.351▼ | 31.304▼ | 29.180▼ | 38.340▼ | 46.701▼ |
| STOCH | 32.500 | 27.844 | 12.164▼ | 57.061 | 59.434 |
| WILL %R | -33.333 | -82.540▼ | -90.116▼ | -94.273▼ | -83.594▼ |
| CCI | -16.908 | -59.837 | -76.262 | -166.634▼ | -65.259 |
| RSI | $LRMR RSI(14) Crossed Below 50 | Set Alert |
| ▼ MACD | $LRMR MACD(12,26,9) Crossed Below Signal Line | Set Alert |
| MA | $LRMR Price Crossed Below MA(50) | Set Alert |
| MA | $LRMR Price Crossed Below MA(26) | Set Alert |
| MA | $LRMR Price Crossed Below MA(13) | Set Alert |
| MA | $LRMR Price Crossed Below MA(7) | Set Alert |
| ▼ GAP | $LRMR Open Gap Down %5 | Set Alert |
| ▼ GAP | $LRMR Open Gap Down %3 | Set Alert |
| ▼ GAP | $LRMR Open Gap Down %2 | Set Alert |
| ▼ BREAK | $LRMR Price Breaks 30 Days Low | Set Alert |
| ▼ BREAK | $LRMR Price Breaks 20 Days Low | Set Alert |
| ▼ BREAK | $LRMR Price Breaks 10 Days Low | Set Alert |
|
Monday, September 29, 2025 08:34 AM
Investing.com -- Larimar Therapeutics Inc (NASDAQ:LRMR) stock plummeted 22.5% on Monday after the company revealed seven participants experienced anaphylaxis in its ongoing open-label study of ...
|
|
Monday, September 29, 2025 08:20 AM
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injec ...
|
|
Monday, September 29, 2025 04:11 AM
In 4 completed studies and the ongoing OL study, 65 participants received at least 1 dose of nomlabofusp, including 39 in the OL study, with 14 on treatment for at least 6 months and 8 for over 1 year ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/09/25 | 3.33 | 3.50 | 3.17 | 3.23 | 6,458,169 |
| 29/09/25 | 3.56 | 4.00 | 3.10 | 3.38 | 23,784,277 |
| 26/09/25 | 4.89 | 5.37 | 4.89 | 5.095 | 3,754,693 |
| 25/09/25 | 5.08 | 5.17 | 4.53 | 4.86 | 2,955,938 |
| 24/09/25 | 4.385 | 5.21 | 4.26 | 5.10 | 7,809,139 |
| 23/09/25 | 4.47 | 4.6288 | 4.405 | 4.44 | 1,904,498 |
| 22/09/25 | 4.16 | 4.58 | 4.06 | 4.48 | 2,715,589 |
| 19/09/25 | 4.32 | 4.365 | 4.13 | 4.20 | 2,384,657 |
| 18/09/25 | 4.14 | 4.29 | 4.125 | 4.28 | 861,025 |
| 17/09/25 | 4.00 | 4.2792 | 3.99 | 4.08 | 1,533,091 |
|
|
||||
|
|
||||
|
|